RT Journal Article
SR Electronic
T1 The Heart Protection Study: High-risk patients benefit from statins, regardless of LDL-C level
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP 991
OP 997
VO 70
IS 11
A1 Gurm, Hitinder S.
A1 Hoogwerf, Byron
YR 2003
UL http://www.ccjm.org/content/70/11/991.abstract
AB The landmark Heart Protection Study (Lancet 2002; 360:7–22) found benefit in treating subjects at high risk of a coronary event with simvastatin 40 mg daily, regardless of baseline low-density lipoprotein cholesterol level and in all subgroups, including women and the elderly. The study found no benefit of simvastatin therapy in preventing noncardiac events (eg, dementia, osteoporotic fractures), and no negative effects, such as an increase in cancer, respiratory disease, or suicide.